The present application relates to compounds with dual pharmacological activity against both the sigma receptor (s) and the opioid receptor, and more particularly to diazaspiroundecane compounds exhibiting this pharmacological activity, to processes for preparing such compounds, to pharmaceutical compositions comprising them already its use in therapy, in particular for the treatment of pain. Claim 1: Compound of formula (1) where R¹ is C₁₋₆ substituted or unsubstituted alkyl, C₂₋₆ substituted or unsubstituted alkenyl, C₂₋₆ substituted or unsubstituted alkynyl, C₃₋₆ substituted or unsubstituted cycloalkyl,e. Replace or not replace c83324c833183277cqulqulo, in R1, if it is replaced by liquid tar, replace it with the alternative selected from - r83088；Halogen, sr8308；-Cn, halogen - No. 83088r83088；If the tar, aluminum and tar in R1 area are replaced, they will be replaced by the substitute selected from halogen-cn and halogen-1； R2 is the substitute or unsubstituted single ring anode or single ring anode, the substitute or unsubstituted single ring anode, or the different ring anode in R2 area,If it is replaced, replace it with the alternative selected from - r830808；-Or83088,Halogen, = o-och8322； - ch8322； - sr8308；-S (O) RS (O) R-CN haloalquilo -haloalcoxi -NR R-No.8322；-8308； C (o) r8308；-8308； 18322； 83088；-C (O) OR-C (O) NR R-8308； C (o) 8308； r8308；-S (O) NR R- 8308th；]R³ is C₁₋₆ substituted or unsubstituted alkyl, C₂₋₆ substituted or unsubstituted alkenyl, C₂₋₆ substituted or unsubstituted alkynyl, C₃₋₆ substituted or unsubstituted cycloalkyl, Cqu substituted or unsubstituted alkylcycloalkyl, C₄₋ alkylaryl ₇ substituted or unsubstituted； substituted or unsubstituted C₃₋₆ aryl, substituted or unsubstituted C₃₋₆ heterocyclyl, substituted or unsubstituted C₄₋₇ alkylheterocyclyl, where the aryl, heterocyclyl or cycloalkyl in R³ if substituted (also alkylaryl, alkylcycloalkyl or alkylheterocyclyl) are substituted with substituents selected from -R⁴,-Or83088,Halogen,
